Cantor Fitzgerald Reaffirms “Overweight” Rating for ADMA Biologics (NASDAQ:ADMA)

ADMA Biologics (NASDAQ:ADMA)‘s stock had its “overweight” rating restated by equities research analysts at Cantor Fitzgerald in a research note issued on Friday, Benzinga reports. They presently have a $20.00 target price on the biotechnology company’s stock. Cantor Fitzgerald’s price objective suggests a potential upside of 0.40% from the stock’s current price.

Other analysts have also issued research reports about the company. Mizuho increased their price objective on ADMA Biologics from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Thursday, June 20th. HC Wainwright boosted their price objective on shares of ADMA Biologics from $10.00 to $18.00 and gave the company a “buy” rating in a research report on Monday, August 12th. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $15.50.

ADMA Biologics Price Performance

Shares of ADMA Biologics stock traded up $0.18 on Friday, hitting $19.92. The company’s stock had a trading volume of 1,340,748 shares, compared to its average volume of 3,190,974. The company has a market capitalization of $4.62 billion, a P/E ratio of -1,001.50 and a beta of 0.61. ADMA Biologics has a 52-week low of $3.06 and a 52-week high of $20.06. The firm has a fifty day moving average price of $15.63 and a 200-day moving average price of $10.83. The company has a quick ratio of 2.80, a current ratio of 6.87 and a debt-to-equity ratio of 0.74.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings data on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share for the quarter, topping analysts’ consensus estimates of $0.08 by $0.05. ADMA Biologics had a net margin of 10.53% and a return on equity of 38.79%. The business had revenue of $107.20 million during the quarter, compared to analysts’ expectations of $86.44 million. During the same period last year, the company posted ($0.02) EPS. The company’s revenue was up 78.4% on a year-over-year basis. On average, equities research analysts expect that ADMA Biologics will post 0.49 earnings per share for the current fiscal year.

Insider Buying and Selling

In other ADMA Biologics news, Director Young Kwon sold 60,000 shares of ADMA Biologics stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $18.26, for a total value of $1,095,600.00. Following the transaction, the director now owns 241,441 shares in the company, valued at approximately $4,408,712.66. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other ADMA Biologics news, Director Young Kwon sold 60,000 shares of ADMA Biologics stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $18.26, for a total transaction of $1,095,600.00. Following the transaction, the director now directly owns 241,441 shares of the company’s stock, valued at $4,408,712.66. The sale was disclosed in a filing with the SEC, which is available at this link. Also, COO Kaitlin M. Kestenberg-Messina sold 24,150 shares of the stock in a transaction on Friday, August 30th. The stock was sold at an average price of $16.90, for a total transaction of $408,135.00. Following the completion of the sale, the chief operating officer now directly owns 449,088 shares of the company’s stock, valued at approximately $7,589,587.20. The disclosure for this sale can be found here. Over the last quarter, insiders sold 466,900 shares of company stock valued at $8,224,121. Insiders own 3.70% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. D. E. Shaw & Co. Inc. raised its holdings in shares of ADMA Biologics by 26.8% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 6,824,517 shares of the biotechnology company’s stock valued at $76,298,000 after buying an additional 1,442,799 shares during the period. Assenagon Asset Management S.A. boosted its holdings in ADMA Biologics by 1.1% in the second quarter. Assenagon Asset Management S.A. now owns 3,382,174 shares of the biotechnology company’s stock valued at $37,813,000 after purchasing an additional 35,707 shares during the last quarter. Driehaus Capital Management LLC grew its stake in ADMA Biologics by 17.3% during the 2nd quarter. Driehaus Capital Management LLC now owns 3,028,667 shares of the biotechnology company’s stock valued at $33,860,000 after purchasing an additional 447,743 shares in the last quarter. Mesirow Institutional Investment Management Inc. acquired a new position in shares of ADMA Biologics in the 1st quarter valued at approximately $17,221,000. Finally, Renaissance Technologies LLC boosted its stake in shares of ADMA Biologics by 28.7% during the 2nd quarter. Renaissance Technologies LLC now owns 2,582,135 shares of the biotechnology company’s stock valued at $28,868,000 after buying an additional 575,100 shares during the last quarter. Institutional investors and hedge funds own 75.68% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.